2022, Maeda H, Uchida M, Kusano M, Tsukamoto K, Yamanoi M. Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021. Clin Pharmacol Ther. 2022 May 15. doi: 10.1002/cpt.2641. 2022年5月15日 論文
2022, Maeda H, Ng Daniel Bin. Regulatory approval with real-world data from regulatory science perspective in Japan. Front Med 2022, 10.3389/fmed.2022.864960. 2022年4月16日 論文
2022, Miyazaki T, Komiyama M, Matsumaru N, Maeda H, TsukamotoK. Lag Time for New Innovative, First-in-Class, Drug Approval in Japan. Biol Pharm Bull. 2022 Apr; 45(4): 477-482. 2022年4月4日 論文
2022, Maeda H. The Current status and future direction of clinical research in Japan. From a regulatory perspective. Front Med 2022, 10.3389/fmed.2021.672095. 2022年1月1日 論文
2021, Maeda H, Okabe A, Sakakura K, Ng DB, Akazawa M. Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan. BMC Health Serv Res. 2021 Dec 11;21(1):1329. doi: 10.1186/s12913-021-07360-w. 2021年12月11日 論文
2021, Satoh M, Motokawa K, Uesawa Y, Ishikawa Y, Maeda H, Iida K, Tanaka H, Kosugi T, Nishizawa K. Study of the compatibility of oral magnesium oxide preparations sold in Japan with the ICH-Q3D guideline for elemental impurities. Drug Discov Ther. 2021 Nov 21;15(5):227-235. doi: 10.5582/ddt.2021.01078. 2021年11月21日 論文
2021, Maeda H, Fukuda Y, Uchida M. Assessment of drugs approved by public knowledge-based applications (Kouchi-shinsei) during the last two decades in Japan. Clin Pharmacol Ther. 2021 Oct;110(4):1127-1135. doi: 10.1002/cpt.2332. 2021年10月1日 論文
2021, Maeda H, Takeda K, Urushihara H, Kurokawa T. Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer. Cancer Report 2021 Jun;4(3): e1334. doi:10.1002/cnr2.1334. 2021年6月1日 論文
2021, Maeda H. Japan’s special approval for emergency system during the COVID-19 pandemic. Clin Pharmacol Ther 2021 May 25: doi:10.1002/cpt.2310. 2021年5月25日 論文
2021, Maeda H. Medical affairs in pharmaceutical companies and related pharmaceutical regulations in Japan. Front Med 2021: doi: 10.3389/fmed.2021.672095. 2021年1月1日 論文
